Jodi Segal
Overview
Explore the profile of Jodi Segal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
909
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Desai R, Varma V, Mahesri M, Lee S, Freedman A, Gerhard T, et al.
Clin Pharmacol Ther
. 2025 Feb;
PMID: 39935003
We evaluated whether drugs approved for other indications that also target metabolic drivers of Alzheimer's disease and related dementia (ADRD) pathogenesis are associated with delayed onset of ADRD. Using routinely...
2.
Segal J, DeGrazia Jr R, Pitts S, Brown K, Taualii M
J Prim Care Community Health
. 2023 Nov;
14:21501319231204590.
PMID: 37981732
Aims: There is a paucity of efficient processes for collecting information in a primary care setting to connect patients afflicted with type 2 diabetes to valuable resources. The objective of...
3.
Akenroye A, Ryan T, McGill A, Zhou G, Shier J, Segal J
J Allergy Clin Immunol Pract
. 2022 Nov;
11(3):946-948.e1.
PMID: 36384205
No abstract available.
4.
Akenroye A, Zhou G, Jackson J, Segal J, Alexander G, Singh S
Allergy
. 2022 Oct;
78(4):1116-1119.
PMID: 36286487
No abstract available.
5.
Akenroye A, Lassiter G, Jackson J, Keet C, Segal J, Alexander G, et al.
J Allergy Clin Immunol
. 2022 Jun;
150(5):1097-1105.e12.
PMID: 35772597
Background: The comparative safety and efficacy of the biologics currently approved for asthma are unclear. Objective: We compared the safety and efficacy of mepolizumab, benralizumab, and dupilumab in individuals with...
6.
Desai R, Varma V, Gerhard T, Segal J, Mahesri M, Chin K, et al.
JAMA Netw Open
. 2022 Apr;
5(4):e226567.
PMID: 35394510
Importance: Cytokine signaling, including tumor necrosis factor (TNF) and interleukin (IL)-6, through the Janus-kinase (JAK)-signal transducer and activator of transcription pathway, was hypothesized to attenuate the risk of Alzheimer disease...
7.
Benkeser D, Diaz I, Luedtke A, Segal J, Scharfstein D, Rosenblum M
Biometrics
. 2021 May;
77(4):1492-1494.
PMID: 34050931
No abstract available.
8.
Andersen K, Mehta H, Palamuttam N, Ford D, Garibaldi B, Auwaerter P, et al.
Clin Infect Dis
. 2021 Jan;
73(11):e4124-e4130.
PMID: 33410884
Background: It is unclear whether chronic use of immunosuppressive drugs worsens or improves the severity of coronavirus disease 2019 (COVID-19), with plausible mechanisms for both. Methods: Retrospective cohort study in...
9.
Desai R, Varma V, Gerhard T, Segal J, Mahesri M, Chin K, et al.
Alzheimers Dement (N Y)
. 2020 Dec;
6(1):e12095.
PMID: 33304987
Drug discovery for disease-modifying therapies for Alzheimer's disease and related dementias (ADRD) based on the traditional paradigm of experimental animal models has been disappointing. We describe the rationale and design...
10.
Rothmann M, Crown W, Louis T, Permutt T, Ruberg S, Segal J, et al.
Pharm Stat
. 2020 Oct;
20(5):952-964.
PMID: 33118319
Clinical trials are primarily conducted to understand the average effects treatments have on patients. However, patients are heterogeneous in the severity of the condition and in ways that affect what...